Wednesday, 10 April 2013

Subdividing Lipoproteins - pattern A and pattern B: The Diet-Heart Hypothesis:

Whole Health Source: The Diet-Heart Hypothesis: Subdividing Lipoproteins

Two posts ago, we made the rounds of the commonly measured blood lipids (total cholesterol, LDL, HDL, triglycerides) and how they associate with cardiac risk. It's important to keep in mind that many things associate with cardiac risk, not just blood lipids. For example, men with low serum vitamin D are at a 2.4-fold greater risk of heart attack than men with higher D levels. That alone is roughly equivalent to the predictive power of the blood lipids you get measured at the doctor's office. Coronary calcium scans (a measure of blood vessel calcification) also associate with cardiac risk better than the most commonly measured blood lipids.

Lipoproteins Can be Subdivided into Several Subcategories

In the continual search for better measures of cardiac risk, researchers in the 1980s decided to break down lipoprotein particles into sub-categories. One of these researchers is Dr. Ronald M. Krauss. Krauss published extensively on the association between lipoprotein size and cardiac risk, eventually concluding (
source):
The plasma lipoprotein profile accompanying a preponderance of small, dense LDL particles (specifically LDL-III) is associated with up to a threefold increase in the susceptibility of developing [coronary artery disease]. This has been demonstrated in case-control studies of myocardial infarction and angiographically documented coronary disease.
Krauss found that small, dense LDL (sdLDL) doesn't travel alone: it typically comes along with low HDL and high triglycerides*. He called this combination of factors "lipoprotein pattern B"; its opposite is "lipoprotein pattern A": large, buoyant LDL, high HDL and low triglycerides. Incidentally, low HDL and high triglycerides are hallmarks of the metabolic syndrome, the quintessential modern metabolic disorder.

Krauss and his colleagues went on to hypothesize that sdLDL promotes atherosclerosis because of its ability to penetrate the artery wall more easily than large LDL. He and others subsequently showed that sdLDL are also more prone to oxidation than large LDL (
1, 2).

Diet Affects LDL Subcategories

The next step in Krauss's research was to see how diet affects lipoprotein patterns. In 1994, he published a
study comparing the effects of a low-fat (24%), high-carbohydrate (56%) diet to a "high-fat" (46%), "low-carbohydrate" (34%) diet on lipoprotein patterns. The high-fat diet also happened to be high in saturated fat-- 18% of calories. He found that (quote source):
Out of the 87 men with pattern A on the high-fat diet, 36 converted to pattern B on the low-fat diet... Taken together, these results indicate that in the majority of men, the reduction in LDL cholesterol seen on a low-fat, high-carbohydrate diet is mainly because of a shift from larger, more cholesterol-enriched LDL to smaller, cholesterol-depleted LDL [sdLDL].
In other words, in the majority of people, high-carbohydrate diets lower LDL cholesterol not by decreasing LDL particle count (which might be good), but by decreasing LDL size and increasing sdLDL (probably not good). This has been shown repeatedly, including with a 10% fat diet and in children. However, in people who already exhibit pattern B, reducing fat does reduce LDL particle number. Keep in mind that the majority of carbohydrate in modern America comes from wheat and sugar.

Krauss then specifically explored the effect of saturated fat on LDL size (free full text). He re-analyzed the data from the study above, and found that:
In summary, the present study showed that changes in dietary saturated fat are associated with changes in LDL subclasses in healthy men. An increase in saturated fat, and in particular, myristic acid [as well as palmitic acid], was associated with increases in larger LDL particles (and decreases in smaller LDL particles). LDL particle diameter and peak flotation rate [density] were also positively associated with saturated fat, indicating shifts in LDL-particle distribution toward larger, cholesterol-enriched LDL.
Participants who ate the most saturated fat had the largest LDL, and vice versa. Kudos to Dr. Krauss for publishing these provocative data. It's not an isolated finding. He noted in 1994 that:
Cross-sectional population analyses have suggested an association between reduced LDL particle size and relatively reduced dietary animal-fat intake, and increased consumption of carbohydrates.
Diet Affects HDL Subcategories

Krauss also tested the effect of his dietary intervention on HDL. Several studies have found that the largest HDL particles, HDL2b, associate most strongly with HDL's protective effects (more HDL2b = fewer heart attacks). Compared to the diet high in total fat and saturated fat, the low-fat diet decreased HDL2b significantly. A separate study found that the effect persists at one year. Berglund et al. independently confirmed the finding using the low-fat American Heart Association diet in men and women of diverse racial backgrounds. Here's what they had to say about it:
The results indicate that dietary changes suggested to be prudent for a large segment of the population will primarily affect [i.e., reduce] the concentrations of the most prominent antiatherogenic [anti-heart attack] HDL subpopulation.
Saturated and omega-3 fats selectively increase large HDL. Dr. B. G. of Animal Pharm has written about this a number of times.

Wrapping it Up

Contrary to the simplistic idea that saturated fat increases LDL and thus cardiac risk, total fat and saturated fat have a complex influence on blood lipids, the net effect of which is unclear, but is associated with a lower risk of heart attacks. These blood lipid changes persist for at least one year, so they may represent a long-term effect. It's important to remember that the primary sources of carbohydrate in the modern Western diet are wheat and sugar. Are the blood lipid patterns that associate with heart attack risk in Western countries partially acting as markers of wheat and sugar intake?

* This is why you may read that small, dense LDL is not an "independent predictor" of heart attack risk. Since it travels along with a particular pattern of HDL and triglycerides, in most studies it does not give information on cardiac risk beyond what you can get by measuring other lipoproteins.

LDL/HDL particle number (LDL/HDL-P) - Clinical Evidence

LipoScience - About Us - Clinical Evidence

LDL particle number (LDL-P) and HDL particle number (HDL-P) measured by NMR have been shown to have significant and independent associations with cardiovascular disease events regardless of LDL cholesterol (LDL-C) levels.

Click here to view a partial bibliography.

Click on the links below to view select abstracts

High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: Multi-Ethnic Study of Atherosclerosis (MESA) J Am Coll Cardiol 2012;60:508-16

Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists Journal of Clinical Lipidology, 2011;5(5);338-367

Clinical Implications of Discordance between Low-Density Lipoprotein Cholesterol and Particle Number: Multi-Ethnic Study of Atherosclerosis Journal of Clinical Lipidology, 2011;5(2);105-113

Underappreciated Opportunities for Low Density Lipoprotein Management in Patients with Cardiometabolic Risk Atherosclerosis. 2010;213:1-7

Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clinical Chemistry. 2009;55:407-419

Low Density Lipoprotein and Apolipoprotein B: Clinical Use in Patients with Coronary Heart Disease Current Cardiology Reports. 2009;11:468-475

Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 2008;31(4);811-812

LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL Management J Clin Lipidology. 2007;1:583-592

Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclass Predict Coronary Events and are Favorably Changed by Gemfibrozil Thearpy in the veterans Affairs High-Density Lipoprotein Intervention Trial Circulation. 2006;113:1556-1563

Tuesday, 9 April 2013

LDL-P - A Better Predictor Of Cardiovascular Risk Than LDL-C

LDL-P - A Better Predictor Of Cardiovascular Risk Than LDL-C

10/19/2005 5:12:08 PM


NEW ORLEANS, Nov. 9 /PRNewswire/ -- LipoScience ( http://www.liposcience.com/ ) announced today the results of a major study confirming that the number of LDL particles (LDL-P) measured by nuclear magnetic resonance (NMR) spectroscopy provides better prediction of heart disease risk than levels of LDL cholesterol (LDL-C). LDL particles are the spherical "containers" that transport cholesterol throughout the body. Excessive numbers of these particles enter at the artery wall to cause atherosclerosis, which can lead to heart attack and stroke.

In a paper presented by Ernst J. Schaefer, M.D., and co-investigators from the Framingham Heart Offspring Study, LDL-P was shown to provide significantly more information about cardiovascular risk in middle-aged men and women followed prospectively over eight years than traditional cholesterol measures. The risk associated with elevated LDL-P was independent not only of LDL and HDL cholesterol, but also of non-lipid risk factors such as age, high blood pressure, diabetes, and smoking. The results were presented as part of the American Heart Association Scientific Sessions 2004.

The study involved the analysis of frozen blood samples obtained from 1,529 men and 1,708 women who were followed for an average period of eight years to monitor the development of cardiovascular disease (CVD), defined as fatal and non-fatal myocardial infarction and stroke, claudication and angina. Two hundred twenty men and 116 women developed CVD during the follow-up period (14.4 percent and 6.8 percent, respectively). LDL particle numbers, as well as numbers of large and small LDL particle subclasses, were obtained by NMR LipoProfile(R) testing at LipoScience in Raleigh, N.C.

Statistical analysis showed that levels of LDL-P and the small LDL particle subclass were significantly more predictive of CVD events than LDL-C or the large LDL particle subclass, after taking into account the risk contributed by established non-lipid risk factors.

Dr. Schaefer, a professor at Tufts University School of Medicine in Boston and chief of the Lipid Metabolism Laboratory, explained that many high-risk individuals have LDL particles that are smaller and contain less cholesterol than normal. As a result, even those with optimal LDL cholesterol levels may still have elevated, far from optimal numbers of atherogenic LDL particles. "The good news is that once these patients are identified, their LDL-P elevations can be treated effectively with the same proven therapies that lower LDL cholesterol," said Schaefer.

Among the patients expected to benefit from LDL particle testing are those with pre-existing heart disease, diabetes or a family history of heart disease. Patients with elevated triglycerides and other characteristics of the metabolic syndrome also are likely to have higher LDL-P levels than indicated by LDL-C testing, Schaefer said.

About the NMR LipoProfile test

Developed by James D. Otvos, Ph.D., and coworkers at North Carolina State University and introduced commercially in 1997, the NMR LipoProfile test employs novel magnetic resonance technology to measure directly the numbers of lipoprotein particles of different size in a patient's blood. Large, medium and small particle subclasses of VLDL, LDL and HDL are measured simultaneously in a rapid and fully automated process. LipoScience provides a patient's physician with a computerized report containing this lipoprotein particle information, highlighting abnormalities, to help guide individualized treatment decisions.

In addition, the NMR LipoProfile test is used in a wide range of clinical studies conducted by government, academic and pharmaceutical company researchers. By illuminating relationships between lipoprotein particles and cardiovascular disease, diabetes and other disorders, these studies seek to develop more effective prevention and treatment strategies. Results previously reported from the Cardiovascular Health Study, Women's Health Study, PLAC-I and VA-HIT, among others, have all shown LDL-P to predict future cardiovascular disease better than LDL-C. The present findings from the Framingham Offspring Study confirm and extend these earlier reports.

About LipoScience, Inc.

Headquartered in Raleigh, N.C., LipoScience develops and markets new clinical applications of NMR spectroscopy in the areas of cardiovascular disease and metabolic disorders. Its flagship product, the NMR LipoProfile blood test, was introduced for clinical research in 1997 and for use in patient care in 1999. The test provides a direct and accurate count of the numbers of atherogenic LDL particles (LDL-P) and VLDL particles of different size, as well as the numbers of protective HDL particles. It is ideally suited for patients who are being considered for or who are currently on LDL- lowering therapy -- patients considered to be at moderately-high or high risk for having a cardiovascular event. The lipoprotein particle information is used as an adjunct to traditional cholesterol measures to help physicians assess and manage their patient's risk of cardiovascular disease more effectively.
Founded in 1994, LipoScience markets and sells the NMR LipoProfile test to physicians, other healthcare professionals, commercial diagnostic laboratories and clinical research clients. LipoScience works with prominent healthcare organizations such as the Centers for Disease Control and Prevention, National Institutes of Health, Mayo Clinic, Harvard Medical School, Johns Hopkins, Columbia University, Northwestern University and Duke University, as well as most of the major pharmaceutical companies on a wide variety of research initiatives. To date, over 1.4 million NMR LipoProfile tests have been performed.

Onsite Interviews Available

Interviews at the AHA Scientific Sessions in New Orleans are available with:
- Dr. Ernst Schaefer, professor of medicine at Tufts University, by calling 781-258-1454. - Dr. James Otvos, founder and chief scientific officer of LipoScience, by calling 919-306-4430.
For more information, please contact Michelle Turenne at 919-306-4430 (cell) or mturenne@liposcience.com.

LipoScience, Inc.
CONTACT: Michelle Turenne of LipoScience, Inc., +1-919-256-1306, orcell, +1-919-306-4430, or mturenne@liposcience.com

 

What's your LDL-P and why should you care?

What's your LDL-P and why should you care?

Richmond.com column
April 2008
For what a man would like to be true, that he more readily believes.
Francis Bacon

Last week the American College of Cardiology (ACC) and American Diabetes Association (ADA) issued a consensus statement saying that the measurement of LDL particle number (LDL-P) is a more accurate method of quantifying cardiovascular risk than traditional measurement of LDL cholesterol (LDL-C).

OK, so what? Well remember, this is a column on health and new discoveries and treatments to test; treat and prevent illness and disease. Both men and women's number one health challenge is heart attack and stroke and since the 50's medicine has been screaming about cholesterol so any new test or strategy to better manage this risk IS big news. The funny thing is this test has been around since 1999. Medicine is slow to change, so it may be up to you to ask your doctor is this test is right for you.

Now for some basic science, keep reading, don't be afraid. Cholesterol is a naturally occurring substance in all our bodies and important for many things like making hormones, cell membranes and insulating the nerves in your brain. Cholesterol is carried in particles within our blood called lipoproteins. There are several types of lipoproteins including High Density lipoproteins (HDL), Low Density lipoproteins (LDL), Intermediate Density lipoproteins (IDL) and Very Low Density lipoproteins (VLDL). Within these various subclasses, there are still more distinctions which relate to particle size and function.

An American doctor, Ancel Keys, in 1953 using data from his 'Seven Countries Study', concluded that diets high in fat resulted in more heart disease. Thus, the start to find "the" substance that caused this increase in disease. Early science identified elevated levels of total cholesterol as being highly correlated to heart disease and stroke.

Much of our current practice of cholesterol management has come from information derived from the Framingham Heart Study, which started in 1948 and goes on today. During these early times, laboratory technology limits allowed only the measurement of total cholesterol and later discoveries allowed the refinement into the above mentioned subclasses.

We now know that it is the number of particles that carry cholesterol in the bloodstream, not the total amount of cholesterol that causes vascular disease. As the concentration of particles goes up inside the bloodstream, the more likely these particles are to enter the wall of the vessel resulting in the deposition of cholesterol inside the vessel wall, the earliest form of vascular disease. LDL-P is the measurement of these cholesterol transport particles.

Since 1999 LipoScience in Raleigh, NC, has been measuring the number of lipoprotein particles which carry cholesterol in our blood. This technology has resulted in large scale testing of LDL-P and has been used to retest the serum of patients in the Framingham Heart Study. This data shows people from the Framingham study who are in the lowest quartile of LDL cholesterol (LDL-C) measurement still had 37%  MORE cardiovascular events than those in the lowest quartile of LDL particle (LDL-P) measurement. In other words, you can have low cholesterol and still be at risk for vascular disease. This data is supported by another large trial more recently called the Multi-Ethnic Study of Atherosclerosis (MESA) trial.

Again, so what? Well here's the thing. There is something called discordance. Discordance is when your cholesterol measured by old fashion means, differs from your lipoprotein particle number. It is the number of lipoproteins which carry your cholesterol that is the BEST estimate of your cardiovascular risk, that thing that kills most of us, not your cholesterol level. If you cholesterol level looks low and you have discordance between your cholesterol level and your lipoprotein particle number, you can still be at a much greater risk; 37% greater in the Framingham study and that was in the people with the LOWEST LDL cholesterol!

I had the opportunity to recently visit the LipoScience headquarters and listen to Dr. William Cromwell their former Chief Medical Officer. Dr. Cromwell has spent the last 20 years researching the relationships of lipoprotein particles and vascular disease. LipoScience uses nuclear magnetic resonance to count the number of lipoprotein particles in a blood sample. Their technology has been available since 1999 and last week's policy statement from the ACC/ADA is the loudest pronouncement yet to the medical community to use this test for routine screening and ongoing management of elevated lipoproteins.

So, what your LDL-P?  I hope you have found this topic of interest, you should. Heart disease and stroke are preventable with today's proven technology. LDL-P is just one of several recent advances that are available to better understand your health risks. Carotid artery ultrasound scanning, high resolution coronary CT scanning, other high tech vascular inflammatory markers are all available to you to better predict your vascular risk. Many of these tests are not covered by your health insurance. Our medical system is ranked 37th worldwide in preventative care. Health insurance companies exist to make money for their shareholders, not take care of your health. You should take care of your health!

Putting all these tests together, explaining their meaning, planning a your wellness program, making healthcare convenient and delivering it in an efficient manner is what the Executive Health Evaluation program does for 10 of the 13 Fortune 1000 companies here in Richmond.

Hypercholesterolemia Diagnosis - Wikipedia

Hypercholesterolemia Diagnosis - Wikipedia

Interpretation of Cholesterol levels
cholesterol type mg/dL mmol/L interpretation
total cholesterol under 200 under 11.1 desirable[20]
200-239 11.1-13.3 borderline[20]
more than 240 more than 13.3 high[20]
LDL cholesterol under 100 under 5.55 most desirable[20]
100-129 5.55-7.15 good[20]
130-159 7.15-8.82 borderline high[20]
160-189 8.82-10.5 high and undesirable[20]
over 190 over 10.5 very high[20]
HDL cholesterol under 40 under 2.21 undesirable; risk increased[20]
41-59 2.21-3.27 okay, but not optimal[20]
60 3.27 good; risk lowered[20]
Indications to lower LDL cholesterol
Persons whose coronary risk is... because they have... should consider lowering LDL if the level is over... and LDL reduction is indicated if the level is over...
high greater than 20% risk of heart attack in 10 years, or an extreme risk factor such as coronary heart disease, diabetes, peripheral-artery disease, carotid-artery disease, or aortic aneurysm 70 mg/dL, 3.88 mmol/dL especially if there are risk factors[21] 100 mg/dL, 5.55 mmol/dL[21]
moderately high a 10-20% risk of heart attack in 10 years and two or more risk factors 100 mg/dL, 5.55 mmol/dL[21] 130 mg/dL, 7.21 mmol/dL[21]
moderate less than 10% risk of heart attack in 10 years and two or more risk factors 130 mg/dL, 7.21 mmol/dL[21] 160 mg/dL, 8.88 mmol/dL[21]
low No risk factors or only one 160 mg/dL, 8.88 mmol/dL[21] 190 mg/dL, 10.5 mmol/dL[21]
Cholesterol is measured as milligrams per deciliter (mg/dL) of blood in the United States and some other countries. In the United Kingdom, most European countries, and Canada, millimoles per liter of blood (mmol/L) is the measure.[22]

For healthy adults, the UK National Health Service recommends total cholesterol of 5 mmol/L or less, and low-density lipoprotein cholesterol (LDL) of 3 mmol/L or less. For people at high risk of cardiovascular disease, the recommendation for total cholesterol is 4 mmol/L or less, and 2 mmol/L or less for LDL.[23]

In the United States, the National Heart, Lung, and Blood Institute within the National Institutes of Health classifies total cholesterol of less than 200 mg/dL as “desirable,” 200 to 239 mg/dL as “borderline high,” and 240 mg/dL or more as “high.”[24]

There is not an absolute cutoff between normal and abnormal cholesterol levels and interpretation of values needs to be made in relation to other health conditions and risk factors.

Higher levels of total cholesterol increase the risk of cardiovascular disease, particularly coronary heart disease. Levels of LDL or non-HDL cholesterol both predict future coronary heart disease, which is the better predictor is disputed.[25] High levels of small dense LDL may be particularly adverse, although measurement of small dense LDL is not advocated for risk prediction.[25] In the past LDL and VLDL levels were rarely measured directly due to cost. Levels of fasting triglycerides were taken as an indicator of VLDL levels (generally about 45% of fasting triglycerides is composed of VLDL), while LDL was usually estimated by the Friedewald formula:
LDL \approx total cholesterol - HDL - (0.2 x fasting triglycerides).
However, this equation is not valid on non-fasting blood samples or if fasting triglycerides are elevated >4.5 mmol/L (> ∼400 mg/dL).

Recent guidelines have therefore advocated the use of direct methods for measurement of LDL wherever possible.[25] It may be useful to measure all lipoprotein subfractions ( VLDL, IDL, LDL, HDL) when assessing hypercholesterolemia and measurement of apolipoproteins and lipoprotein (a) can also be of value.[25] Genetic screening is now advised if a form of familial hypercholesterolemia is suspected.[25]
 -----------------------------------------------------------------------------------------------
See also: High-density lipoprotein#Recommended ranges and Low-density lipoprotein#Normal ranges

Extracts - ATLCX (Episode 29): Dr. Thomas Dayspring | Cholesterol Testing: What Matters Most?

Extracts - ATLCX (Episode 29): Dr. Thomas Dayspring | Cholesterol Testing: What Matters Most?

"LDL particle concentrations is the type of testing we all need to have done"

Listen at the iTunes page for the podcast:

Listen and comment about the show at the official web site for the podcast:

Download the MP3 file of Episode 29 [109:15m]:

5. Listen on the Stitcher app–NO DOWNLOADING


Particle count - big picture

  • HDL-cholesterol has as its surface apoprotein, apolipoprotein A-1
  • ApoA-I measurement serves as an HDL particle count
  • You can have a lot of HDL particles, but low HDL-cholesterol
  • Thus although apoA-I and HDL-C usually correlate, in some folks they do not (discordance)
  • People with low HDL-C but normal apoA-I tend not to get heart disease
  • people with high HDL-cholesterol could have low Apo A-1 (low HDL particle count)

Evidence supporting LDL-P approach?

  • His 2012 study of diabetics looking at LDL particles (American Journal of Cardiology Sept 2012)
  • Check out information on why LDL particle tests good

Official standards?

  • There are 5 US specialty Society guidelines do advise apoB or LDL-P testing
  • These specialty societies are ADA, ACC, AACC, ACE, NLA
  • Apo B is in the European guidelines, but not LDL-P (LDL-P by NMR is not available in Europe)
  • Guidelines are never meant to be cutting edge
  • The majority of doctors don’t know understand or know of Apo B and LDL-P
  •  Apo B is a worldwide standard for lipid/lipoprotein health
  • You can get Apo B test run in any lab in America
  •   The VAP test offers a calculated Apo B–BOGUS!
  • Calculated LDL-cholesterol is an imprecise equation
  • If your trigs are under 100, divide by 5 for VLDL-cholesterol determination
  • Once you have VLDL-C, you can calculate LDL-C using the equation: - LDL-C = TC minus HDL-C – VLDL-C

Particle count - what it should be

  • LDL cholesterol levels under 100 mg/dL has long been the standard
  • LDL-P of 1600 nmol/L is in the 80th percentile
  • A desirable LDL-P of 1000 is the 20th percentile population cut point
  • ie. 80% of the populations has a higher level
  • LDL-P under 700 is in the 5th percentile population cut point
  • ie. 5% of folks are less and 95% are higher

Particle count too high, causation and cure

  • Insulin resistance is at the heart of high LDL-P\
  • cutting carbs will reduce it
  • a low-fat diet (without carb restriction)
  • its the “worst thing you can do” in a person with IR and high LDL-P
  • Drugs are almost always necessary unless you start eating low-carb ASAP

BACKGROUND



Particle count - physiology basics

  • There is one apoB molecule per VLDL, IDL and LDL particle: 
apoB is not on HDL particles
Apo B testing measures how many VLDL, IDL and LDL exists per deciliter of plasma
Apo A-1 particle do not deposit cholesterol in the artery: they may in fact remove it.
  • Apo B particles after entering the artery sticks
  • White blood cells (macrophages) ingest apoB particle carrying cholesterol and initiate inflammation
  • VLDL takes lipids (mostly TG, but also cholesterol) out of the liver;
  • VLDL traffic TG to muscle and fat cells and as TG exit the VLDL shrinks, creating IDLs
  • Most IDLs are cleared at the liver but some IDL shrink and become LDLs
  • Liver isn’t as efficient at clearing LDL particles compared to IDL
  • thus extending LDL plasma residence time
  • A normally composed LDL half-life is 2-3 days; compared to VLDL 2-6 hours or IDL 1-2 hours
  • Thus Apo-B test actually measures LDL-P in the blood (vast majority of apoB particles are LDLs)
  • Can’t change LDL-P by eating carbs day before test (LDL half life is typically 3 days)
  • Takes trigs a few days to alter lipoprotein metabolism and jack up your LDL-P
  • Total cholesterol minus HDL is called non-HDL cholesterol
  • it reveals how much cholesterol is in the apoB particles
  • and thus serves as a better measure of atherogenic apoB particles than does LDL-C
  • However, even Non-HDL cholesterol misses 30% of persons with high apoB (LDL-P) at-risk cases

Triglycerides

  • Triglycerides is a key marker that few health care professionals truly, understand
  • Trigs over 70 in an IR adult, LDL-P needs checking
  • LDL is supposed to carry primarily cholesterol with only small amount of TG (4:1 ratio)
  • Increased LDL/triglyceride level occurs when LDLs are trafficking more TG than normal –
  • in such cases they are therefore carrying less cholesterol than they should
  • These are therefore cholesterol-depleted LDLs.
  • It takes 40-70% more cholesterol-depleted particles to traffic a given amount of cholesterol
  • In such cases we need a therapy to remove triglycerides from LDL
  • High triglycerides/low HDL-cholesterol ratio (> 3.0) is very indicative “insulin resistance”


ApoE genotype

  • What Apo E genotype issues you should be aware of
  • Apo E4 is a marker of elevated risk of heart disease
  • ApoE2 is usually desirable
  • but Apo E2 with high triglycerides is a high risk lipoprotein abnormality
  • ie - with normal LDL-P: but they have too many VLDLs and IDLKs, but not LDLs.
  • Apo E4 is also associated with Alzheimer’s disease
  • A ketogenic diet might ward off Alzheimer’s longer
  • Drown yourself in omega-3 fatty acids” if Apo E4
  • Whether an Apo E4 needs to lower their fat intake is truly not known at present
  • Are they REALLY over-absorbing fat–maybe, maybe not
  • If your lifestyle controls Apo B, no need to worry
  • What one test gives most info on heart disease risk: ApoB and LDL-P
  • No matter what Apo B is, other tests such as inflammatory markers can also tell about CV risk
  • The totality of tests help doctors treat you better
  • Triglycerides and Apo B/LDL-P gets most info needed to start

Discordant test results

  • LDL cholesterol might be low, but LDL-P could be high:
  • How you can have low LDL-cholesterol and yet high LDL-P numbers (discordance)
  • normally the two tests should correlate very well
  • when they do they are concordant and when they do not they are discordant
  • If Apo B and LDL-P come back one high, one normal – discordance is present
  • It happens in 10-12% of people; repeat test again
  • If LDL-P is high and Apo B is normal, there is no consensus on what to do
  • LDL-P tends to “outperform” Apo B as a key marker

LDL particle size

  • Particle size has no bearing on whether LDL enters the artery wall or not
  • Insulin resistant Diabetics typically have the small LDL regardless of LDL-C

Not keen on heart scan testing

  •  What he thinks about having a heart scan conducted
  •  His concern over having a CT scan of your chest: too much radiation



European Atherosclerosis Society | Guidelines

European Atherosclerosis Society | Guidelines

European guidelines on cardiovascular disease prevention in clinical practice

The EAS has pioneered guidelines on the prevention of cardiovascular disease with pan-European campaigns in 1987 and 1988. Recognizing that guidelines endorsed by cardiologists would have greater impact on clinical practice, the EAS joined forces with the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) to issue the first set of joint European Guidelines on Prevention of Coronary Artery Disease in 1994. This collaboration has been expanded over the years.
The current revision of these Guidelines is available through the link below.
Joint European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2012)

ESC-EAS Joint guidelines on management of dyslipidemia

ESC-EAS Joint guidelines on management of dyslipidemia are available from Atherosclerosis and European Heart Journal.
To view the Guidelines, click on the links below.
To download the slideset on ESC-EAS Joint guidelines on management of dyslipidemia, click on the image below.

Hypercholesterolemia - Wikipedia

Hypercholesterolemia - Wikipedia

Hypercholesterolemia (also spelled hypercholesterolaemia) is the presence of high levels of cholesterol in the blood.[1] It is a form of "hyperlipidemia" (elevated levels of lipids in the blood) and "hyperlipoproteinemia" (elevated levels of lipoproteins in the blood).[1]

Cholesterol is a sterol, a sort of fat; see the diagrammatic structure at the right. It is one of three major classes of lipids which all animal cells utilize to construct their membranes and is thus manufactured by all animal cells. Plant cells do not manufacture cholesterol. It is also the precursor of the steroid hormones, bile acids and vitamin D.

Since cholesterol is insoluble in water, it is transported in the blood plasma within protein particles (lipoproteins). Lipoproteins are classified by their density: very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein (HDL).[2] All the lipoproteins carry cholesterol, but elevated levels of the lipoproteins other than HDL (termed non-HDL cholesterol), particularly LDL-cholesterol are associated with an increased risk of atherosclerosis and coronary heart disease.[3] In contrast higher levels of HDL cholesterol are protective.[4]

Elevated levels of non-HDL cholesterol and LDL in the blood may be a consequence of diet, obesity, inherited (genetic) diseases (such as LDL receptor mutations in familial hypercholesterolemia), or the presence of other diseases such as diabetes and an underactive thyroid.[1]

Reducing dietary fat is recommended to reduce total blood cholesterol and LDL in adults.[5] In people with very high cholesterol (e.g. familial hypercholesterolemia) diet is often insufficient to achieve the desired lowering of LDL and lipid lowering medications which reduce cholesterol production or absorption are usually required.[6] If necessary other treatments, including LDL apheresis or even surgery (for particularly severe subtypes of familial hypercholesterolemia) are performed.[6]

Contents

Familial hypercholesterolemia - Wikipedia

Familial hypercholesterolemia - Wikipedia

Familial hypercholesterolemia (abbreviated FH, also spelled familial hypercholesterolaemia) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease. Many patients have mutations in the LDLR gene that encodes the LDL receptor protein, which normally removes LDL from the circulation, or apolipoprotein B (ApoB), which is the part of LDL that binds with the receptor; mutations in other genes are rare.

Heterozygous FH is normally treated with statins, bile acid sequestrants or other hypolipidemic agents that lower cholesterol levels. New cases are generally offered genetic counseling. Homozygous FH often does not respond to medical therapy and may require other treatments, including LDL apheresis (removal of LDL in a method similar to dialysis) and occasionally liver transplantation.[1]

Contents

Dr. Thomas Dayspring | Cholesterol Testing: What Matters Most? - ATLCX (Episode 29):

ATLCX (Episode 29): Dr. Thomas Dayspring | Cholesterol Testing: What Matters Most? « Jimmy Moore's Livin' La Vida Low Carb Blog

In Episode 29 of “Jimmy Moore Presents: Ask The Low-Carb Experts,” we’re very excited to bring to you one of the world’s leading lipidologists and experts on just about everything you could ever want to know about cholesterol numbers named Dr. Thomas Dayspring from LecturePad.org.

He’s the Director of Cardiovascular Education at the Foundation for Health Improvement and Technology in Richmond, Virginia and is one of the most requested speakers in the United States with expertise on atherothrombosis, lipoprotein and vascular biology, advanced lipoprotein testing and more. Dr. Dayspring has given over 4000 lectures in all 50 states educating medical professionals and the lay public alike.

Many of you first heard Dr. Dayspring in Episode 585 of “The Livin’ La Vida Low-Carb Show” podcast and afterwards my listeners had lots of questions for Dr. Dayspring about cholesterol. That’s why we decided to bring him back on ATLCX to take on the topic “Cholesterol Testing: What Matters Most?” so you can speak directly with him about your burning questions on your cholesterol concerns.

This was a golden opportunity to get better clarification on any issues regarding cholesterol testing that concern you. Listen in to hear what Dr. Thomas Dayspring had to say as he took on your questions about the most important factors in cholesterol testing in EPISODE 29 on October 4, 2012.

Listen to Dr. Thomas Dayspring on “Cholesterol Testing: What Matters Most?”:
  • People are concerned (and confused) about cholesterol
  • Gary Taubes/Peter Attia turned him on to community
  • Atheroschlerosis “build-up of cholesterol” in arterial wall
  • Blood tests help doctors determine heart disease risk
  • People with heart disease have cholesterol levels “all over the place”
  • Even persons with seemingly “perfect cholesterol” can get atheroschlerosis
  • Tim Russert is a perfect example of this
  • No human has any cholesterol floating around in blood as a free molecule
  • Lipids must bind to protein to become soluble in water (plasma)
  • Lipids bound to apoproteins are lipoproteins which traffic lipids in plasma
  • This “illegal dump job” (lipoproteins carrying cholesterol into the artery) can lead to atherosclerosis
  • Thus atherogenesis is a lipoprotein-mediated disease
  • Atherogenic lipoproteins (lipoproteins that enter the artery wall) are the “bad guys”
  • The goal is to avoid lipoproteins from penetrating the artery wall
  • We have to have labs that measure lipoprotein concentrations, rather than lipid concentrations
  • This (particle concentrations) is the type of testing we all need to have done
  • Omega-3 and omega-6 fatty acids are within the phospholipids delivered by lipoproteins
  • The types of lipoproteins: VLDL, IDL, LDL and HDL
  • Traditional tests look at cholesterol measurements like the total cholesterol (TC)
  • TC is the amount of cholesterol carried within all of the lipoproteins per deciliter of plasma
  • HDL-cholesterol has as its surface apoprotein, apolipoprotein A-1
  • ApoA-I measurement serves as an HDL particle count
  • You can have a lot of HDL particles, but low HDL-cholesterol
  • Thus although apoA-I and HDL-C usually correlate, in some folks they do not (discordance)
  • People with low HDL-C but normal apoA-I tend not to get heart disease
  • Those with high HDL-cholesterol could have low Apo A-1 (low HDL particle count)
  • There is one apoB molecule per VLDL, IDL and LDL particle: apoB is not on HDL particles
  • Apo B testing measures how many VLDL, IDL and LDL exists per deciliter of plasma
  • Apo A-1 particle do not deposit cholesterol in the artery: they may in fact remove it.
  • Apo B particles after entering the artery sticks
  • White blood cells (macrophages) ingest apoB particle carrying cholesterol and initiate inflammation
  • VLDL takes lipids (mostly TG, but also cholesterol) out of the liver;
  • VLDL traffic TG to muscle and fat cells and as TG exit the VLDL shrinks, creating IDLs
  • Most IDLs are cleared at the liver but some IDL shrink and become LDLs
  • Liver isn’t as efficient at clearing LDL particles compared to IDLthus extending LDL plasma residence time
  • A normally composed LDL half-life is 2-3 days; compared to VLDL 2-6 hours or IDL 1-2 hours
  • Thus Apo-B test actually measures LDL-P in the blood (vast majority of apoB particles are LDLs)
  • Standard LDL cholesterol test may or may not help
  • LDL cholesterol might be low, but LDL-P could be high: normally the two tests should correlate very well: when they do they are concordant and when they do not they are discordant
  • Particle size has no bearing on whether LDL enters the artery wall or not
  • Insulin resistant Diabetics typically have the small LDL regardless of LDL-C
  • How you can have low LDL-cholesterol and yet high LDL-P numbers (discordance)
  • LDL is supposed to carry primarily cholesterol with little TG (4:1 ratio)
  • Increased LDL/triglyceride level occurs when LDLs are trafficking more TG than normal – in such cases they are therefore carrying less cholesterol than they should. These are therefore cholesterol-depleted LDLs.
  • It takes 40-70% more cholesterol-depleted particles to traffic a given amount of cholesterol
  • In such cases we need a therapy to remove triglycerides from LDL
  • High triglycerides/low HDL-cholesterol ratio (> 3.0) is very indicative “insulin resistance”
  • You can’t guess particle levels by looking at TG or cholesterol values provided in traditional test
  • Triglycerides should be well under 100, even below 70 to be physiologic
  • What if you have large LDL particles and normal Apo B (i.e. normal LDL particle count or LDL-P)
  • Total cholesterol minus HDL is called non-HDL cholesterol: it reveals how much cholesterol is in the apoB particles and thus serves as a better measure of atherogenic apoB particles than does LDL-C
  • However, even Non-HDL cholesterol misses 30% of persons with high apoB (LDL-P) at-risk cases
  • Just get an Apo B and/or LDL particle test and know exactly if atherogenic particles are present
  • It’ll be the best money you’ll ever spend on health
  • You can get Apo B test run in any lab in America
  • Why the NMR Lipoprofile test (LDL-P) is the one to get run (nuclear magnetic resonance spectroscopy)
  • LipoScience is the only lab that runs this test now
  • FDA just approved smaller versions of their analyzer for other labs to purchase
  • Two other technologies exist that measure LDL-P, but those methods are “unproven” in clinical trials
  • Everyone needs to know their LDL particle number (LDL-P or apoB)
  • When you order LDL particle test, they also report standard lipid concentrations
  • Even kids should have a LDL-P test if there is a family history of heart disease, high cholesterol or diabetes or if the kids are obese
  • Severely elevated LDL-P disorder can and should be treated early in life
  • But almost nobody is screening these children at all
  • LDL cholesterol levels under 100 mg/dL has long been the standard
  • LDL-P of 1600 nmol/L is in the 80th percentile
  • A desirable LDL-P of 1000 is the 20th percentile population cut point: 80% of the populations has a higher level
  • LDL-P under 700 is in the 5th percentile population cut point: 5% of folks are less and 95% are higher
  • If particle counts are high, nutritional therapy first and then maybe drugs
  • The most common cause of why LDL-P becomes high: insulin resistance
  • You gotta take carbs out of your die to combat IR or take drugs or both
  • Insulin resistance is at the heart of high LDL-P
  • Why NCEP guidelines don’t say anything about LDL-P: Actually 5 US specialty Society guidelines do advise apoB or LDL-P testing
  • Apo B is in the European guidelines, but not LDL-P (LDL-P by NMR is not available in Europe)
  • Guidelines are never meant to take be cutting edge
  • LDL particle tests are more expensive than regular lipid concentrations
  • LDL-P by NMR in a patient without insurance coverage is four times more costly than traditional tests
  • The majority of doctors don’t know understand or know of Apo B and LDL-P
  • If these tests are done, because so many with fine cholesterol levels will have high apoB, drug use will quadruple and third party payers and govenrment does not want that
  • Drugs are almost always necessary unless you start eating low-carb ASAP
  • The low-fat diet (without carb restriction) is the “worst thing you can do” in a person with IR and high LDL-P
  • The specialty societies (ADA, ACC, AACC, ACE, NLA) are on board with new tests
  • Individual patients often have “discordance” between cholesterol measurements and apoB (LDL-P)
  • I convinced my own doctor to start doing NMR testing
  • Dr. Dayspring’s story about personal lipid revelation:
  • Dr. Jim Otvos inventor of NMR LipoProfile in reality likely saved his life: Dr D had a perfect lipid profile, but a very high LDL-P that never would have been discovered without doing the NMR LipoProfile
  • His 2012 study of diabetics looking at LDL particles (American Journal of Cardiology Sept 2012)
  • Check out information on why LDL particle tests good
  • Once LDL is 190 mg/dl, that’s familial hypercholesterolemia
  • Definitely get an Apo B and LDL-P immediately to see the extent of apoB elevation
  • Normal cholesterol and high LDL-P suggests IR and calls for low-carb diet
  • Some low-carbers have “paradoxical” rise in both LDL particles and LDL-C
  • These people might require aggressive use of drugs
  • The drug therapies that are needed for people with FH
  • Most FH take up to 4 medications to control LDL-P
  • Several new drugs are “in the pipeline” coming soon
  • I’ve personally seen my LDL-cholesterol and LDL-P go way up
  • That shouldn’t happen under normal circumstances
  • These people are “enigmas” with potential yet to be discovered genetic abnormalities
  • This doesn’t mean you should stop your low-carb diet
  • If you’re insulin resistant, you need low-carb
  • My current high-fat, low-carb n=1 experiment
  • Apo B is a worldwide standard for lipid/lipoprotein health
  • If patient is stable, it’s not unreasonable to stop statin and test again (no more than 4 weeks later)
  • Statins (can) have downsides, so take off if possible: in general for folk with high apoB the benefit of statins is vastly superior to any downside)
  • Lipoproteins can change drastically in 2-3 weeks with lifestyle and drugs
  • Retest again after one month to see how it goes off statins
  • Any studies looking at low-carb and decreased LDL-P
  • This is the type of thing modern researchers will be doing
  • There’s support for this, but mainly from Atkins diet studies
  • Lifestyle and/or meds reduce risks of high LDL-P
  • Risk of sterols in the development of arterial plaque
  • Watch Part 1 of Dr. Dayspring’s lecture on sterols
  • Cholesterol, a zoosterol, is one sterol; plants also produce sterols called phytosterols
  • Intestines usually push out plant sterols; not always
  • Some make into lipoproteins and penetrate arteries
  • Measuring phytosterols is probably a good idea: they serve as a biomarker of intestinal sterol absorption
  • Physicians are starting to measure this more and more
  • Cholesterol-absorption blockers can reduce intestinal hyperabsorption of sterols
  • Phytosterols sold in stores may be more harmful than good if taken by a person who is a hyperabsorber
  • Humans with normal sterol absorption would not be harmed by phytosterols
  • A hyperabsorber taking phytosterols might lower LDL cholesterol, but raise phytosterols
  • Without assaying sterol absorption These products may not be “heart-healthy” at all, just “hocus pocus”
  • The phytostanol, sitostanol, (Benecol) reduce cholesterol absorption and stanols are not absorbed, so this canbe an excellent functional food that safely lowers LDL-C and LDL-P
  • LDL cholesterol levels may or may not be associated with LDL particle concentrations
  • 20 years ago, in assaying LDL we’d were “extolling” LDL-cholesterol tests
  • Changing things in medicine is a slow, hard road
  • Patients must educate yourself and get what you need done
  • Don’t assume doctors are “genius” on all health matters, especially cardiovascular biomarkers
  • How the various cholesterol numbers are calculated
  • Calculated LDL-cholesterol is an imprecise equation
  • If your trigs are under 100, divide by 5 for VLDL-cholesterol determination: Once you have VLDL-C, you can calculate LDL-C using the equation LDL-C = TC minus HDL-C – VLDL-C
  • Triglycerides is a key marker that few health care professionals truly, understand
  • Trigs over 70 in an IR adult, LDL-P needs checking
  • Large VLDL’s and high total and small LDL-P are markers of insulin resistance
  • Kids need to “get off the damn carbs” and substitute fat and protein instead
  • Whether it’s possible to have “too low” cholesterol
  • You don’t need cholesterol in blood, but in the cells and all cells in the body manufacture it
  • a href=http://en.wikipedia.org/wiki/Hypobetalipoproteinemia>Hypobetalipoproteinemia have low LDL-P (apoB) and very low cholesterol levels
  • These people tend to live a very long life and suffer no cholesterol deficiency issues
  • What Apo E genotype issues you should be aware of
  • Apo E4 is a marker of elevated risk of heart disease”
  • ApoE2 is usually desirable but Apo E2 with high triglycerides is a high risk lipoprotein abnormality with normal LDL-P: they have too many VLDLs and IDLKs, but not LDLs.
  • Apo E4 is also associated with Alzheimer’s disease
  • A ketogenic diet might ward off Alzheimer’s longer
  • “Drown yourself in omega-3 fatty acids” if Apo E4
  • ApoE genotyping just a one-time genetic test you run
  • Whether an Apo E4 needs to lower their fat intake is truly not known at present
  • Are they REALLY over-absorbing fat–maybe, maybe not
  • If your lifestyle controls Apo B, no need to worry
  • What one test gives most info on heart disease risk: ApoB and LDL-P
  • No matter what Apo B is, other tests such as inflammatory markers can also tell about CV risk
  • The totality of tests help doctors treat you better
  • Triglycerides and Apo B/LDL-P gets most info needed to start
  • Christine had 300 trigs, dropped to 130 in 6 weeks
  • Can’t change LDL-P by eating carbs day before test (LDL half life is typically 3 days)
  • Takes trigs a few days to alter lipoprotein metabolism and jack up your LDL-P
  • If Apo B and LDL-P come back one high, one normal – discordance is present
  • It happens in 10-12% of people; repeat test again
  • If LDL-P is high and Apo B is normal, there is no consensus on what to do
  • LDL-P tends to “outperform” Apo B as a key marker
  • Why HDL cholesterol decreases on autoimmune issues
  • Endothelial lipase expressed with such diseases increases HDL catabolism
  • Women with anorexia tend to have transient high cholesterol as adipocytes are a cholesterol storage tissue
  • Wait one month after weight loss and then test again with high LDL-C and LDL-P
  • Thus weight loss can make transiently make your LDL cholesterol seem higher
  • What he thinks about having a heart scan conducted
  • His concern over having a CT scan of your chest: too much radiation
  • Why do I care about this if LDL-P and Apo B is high: the image result would not change therapy
  • Whether LDL-P and Apo B are impacted by non-fasted: NO
  • LDL particles are present in plasma on average 3 days and are is a steady state and thus levels are stable over several days
  • Liposcience does not offer apoB testing: they provide LDL-P by NMR. If you have LDL-P you do not need apoB
  • The VAP test offers a calculated Apo B–BOGUS!
  • You have to insist on a MEASURED Apo B test (using a protein immuno assay)
  • Chris Masterjohn says major deviations in cholesterol
  • You’re “playing with fire” with traditional testing
  • It’s time to say goodbye to these kinds of tests
  • You gotta move on when newer biomarkers come along
  • We must abandon traditional cholesterol testing
  • Get the new tests in there as the standard bearer
  • It’s a “total joke” when heart disease is #1 killer
  • Doctors often think someone advocating particle testing is “some quack”
  • Never be afraid to change doctors if necessary
  • Publisher asked me to write layman’s cholesterol book
  • Peter Attia’s “Straight Dope On Cholesterol” series
  • Your doctor better know Apo B and LDL-P or fire him
  • Dr. Dayspring on Twitter: @DrLipid


  • Dr. Dayspring on Twitter: @DrLipid
     
    TRY THIS NEW LOW-CARB SNACK OPTION FROM NICK’S STICKS:

    NOTICE OF DISCLOSURE: http://cmp.ly/3
    There are five ways you can listen to Episode 29:
    1. LISTEN LIVE ON THURSDAY NIGHTS AT 7PM ET by calling (712) 432-0900 or on Skype at “freeconferencing.7124320900″–whether you call or Skype, be sure to use the access code “848908.” You can listen and even participate on the topic discussion by asking your questions directly to the featured expert.
    2. Listen at the iTunes page for the podcast:

    3. Listen and comment about the show at the official web site for the podcast:

    4. Download the MP3 file of Episode 29 [109:15m]:

    5. Listen on the Stitcher app–NO DOWNLOADING!
  • ‘All Things Lipids (Cholesterol 101)’ | Chris Masterjohn « Jimmy Moore's Livin' La Vida Low Carb Blog

    Ask The Low-Carb Experts (Episode 6): ‘All Things Lipids (Cholesterol 101)’ | Chris Masterjohn « Jimmy Moore's Livin' La Vida Low Carb Blog

    In Episode 6 of “Jimmy Moore Presents: Ask The Low-Carb Experts,” we have Chris Masterjohn from Cholesterol-And-Health.com who is a blogger and doctoral candidate in Nutritional Sciences at the University of Connecticut where he will be graduating this Spring.

    We were so pleased to have him join us on ATLCX answering listener questions about cholesterol and lipids in EPISODE 6 on February 16, 2012.



    Listen to Chris Masterjohn discuss “All Things Lipids (Cholesterol 101)”:


  • Cholesterol plays a variety of very important roles in the body


  • SLOS that underlines the importance of cholesterol to health


  • Cholesterol is essential to life and a healthy pregnancy


  • Lacking cholesterol can lead to significant health problems


  • Cholesterol has been seen as “a very bad thing” incorrectly


  • Scientists call themselves “cholesterol warriors” who oppose


  • The “cholesterol skeptics” are the ones who don’t buy it


  • He believes there is truth in both camps that have merit


  • How we can protective against oxidative degradation of lipids


  • There is a role blood lipids play for metabolic issues


  • The difference between dietary cholesterol and in the body


  • Eating a few eggs a day has no negative effect on cholesterol


  • How to counter a doctor who insists on your taking Lipitor


  • Dr. Duane Graveline who suffered mental damage from statins


  • Statins should not be used as a first line of treatment


  • There’s something concerning about total cholesterol of 300


  • Cholesterol levels of 220-250 seems to be the “normal” range


  • There is no statin deficiency when your cholesterol is high


  • Have several cholesterol readings taken over a few months


  • One high cholesterol reading isn’t a big deal to worry about


  • Keep weight stable for six months before testing for cholesterol


  • Hypothyroidism could be one reason for “high cholesterol”


  • Familial hypocholesterolemia (FH) is serious and should be tested


  • Why he is not a fan of the particle size tests (VAP, NMR)
  • VAP tests tend to give you much higher Pattern B (small) LDL
  • NMR tests tend to give you much higher Pattern A (large) LDL


  • Best predictor of heart disease risk is Total/HDL cholesterol ratio


  • Triglycerides are useful to determine insulin resistance


  • There have not been a lot of studies on particle size


  • No added info provided by particle size than Total/HDL ratio


  • Particle size should remain on “the back burner” for now


  • Whether Lp(a) can be lowered by statins


  • The ideas about Lp(a) and heart disease are controversial


  • Lp(a) could be inflammation or it could just be genetics


  • What a 461 total cholesterol means after “normal” cholesterol


  • She switched from vegetarian to a more traditional diet


  • Her weight has been stable, but her cholesterol is “high”


  • FH could provide an “exaggerated” rise from saturated fat


  • Whether age makes a difference for FH to manifest itself


  • Doctors don’t seem to care if high cholesterol is from FH


  • Homozygous FH is a risk for children from someone with FH


  • Why cholesterol numbers seem to increase during pregnancy


  • Whether MGmin LDL is the silver bullet of atherosclerosis


  • What causes small, dense LDL particles to form


  • Eating a low-carbohydrate diet leads to larger LDL particles


  • What ratio of cholesterol numbers are good vs. bad health


  • It’s ideal to have your Total/HDL cholesterol ratio under 4


  • Whether eating Paleo can drop triglycerides precipitously


  • Doctors seems to give out statins drugs “like candy”


  • Very high triglycerides (700) could be some “crazy genetics”


  • Serious metabolic issues make you ultra-sensitive to carbs


  • Fish oil can lower triglycerides but may not be a good idea


  • Triglycerides going very high from carbs should be checked


  • Kitavans have cholesterol over 200 and are healthy


  • Whether statins can inhibit the formation of arterial plaque


  • There’s some good and a lot of bad that comes from statins


  • Glycation is a misnomer referring mostly to AGEs


  • AGEs have a legitimate role in health, but not in high levels


  • How to explain higher cholesterol readings for life insurance


  • Looking for atheroschlerosis could counter statin pushers


  • Whether Lp(a) is just another way to keep statin drugs alive


  • What can be done to lower Total/HDL cholesterol ratio


  • Get measurements tested a few times over several months


  • A sign of good metabolism when Total/HDL cholesterol ratio is low


  • His response to Dr. Ray Peat’s toxicity of EFAs and PUFAs


  • “How Essential Are The Essential Fatty Acids?”


  • Omega-3/omega-6 fats aren’t necessarily “toxic” at any dose


  • What oils are the highest in PUFAs that need to be avoided


  • What connection lipid volume has with the speed of blood flow


  • Whether lower total cholesterol compromises health benefits


  • Lower cholesterol could mean it’s being used for various functions


  • If Celiac disease could lead to higher total cholesterol


  • What is being measured vs. estimated on cholesterol tests


  • The valuable reasons for testing your cholesterol


  • His story of a man who didn’t test his cholesterol


  • Red yeast rice is a statin which is a derivative of RYR


  • Lovaza is a pharmaceutical level of fish oil


  • High triglycerides and low testosterone is usually the thyroidThere are four ways you can listen to  Episode 6:
  • He is the author of two blogs, The Daily Lipid at Cholesterol-and-Health.Com and Mother Nature Obeyed at WestonAPrice.org.

    Chris Masterjohn is also a frequent contributor to Wise Traditions, the quarterly journal of the Weston A. Price Foundation.
    Chris is the author of five publications in peer-reviewed journals, including a letter to the editor of the Journal of the American College of Cardiology criticizing the conclusions of a widely publicized study about the effect of saturated fat on blood vessel function.

    Also, a letter to the editor of the American Heart Journal arguing that the effect of cholesterol ester transfer protein inhibitors on vitamin E metabolism should be studied before these drugs are deemed safe for preventing heart disease, a hypothesis published in Medical Hypotheses about the molecular mechanism of vitamin D toxicity and the involvement of vitamins A and K in this mechanism.

    Also, a pilot study in humans suggesting that vitamin E protects against some of the negative effects of sugar consumption published in the Journal of Nutritional Biochemistry, and a review published in Nutrition Reviews about the potential for green tea to prevent or treat nonalcoholic fatty liver diseases.

    Chris Masterjohn has thoroughly studied the impact of cholesterol on your health and the answers he has discovered might just surprise you. If you have questions about cholesterol, HDL, LDL, triglycerides and more then this is the podcast for you.

    1. LISTEN LIVE ON THURSDAY NIGHTS AT 7PM ET by calling (712) 432-0900 or on Skype at “freeconferencing.7124320900″–whether you call or Skype, be sure to use the access code “848908.” You can listen and even participate on the topic discussion by asking your questions directly to the featured expert.
    2. Listen at the iTunes page for the podcast:

    3. Listen and comment about the show at the official web site for the podcast:

    4. Download the MP3 file of Episode 6 [76:03m]: